GRI earnings analysis
What we found in GRI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include revenue, margins, EPS, balance-sheet, cash-flow, or segment financial data, so quarterly operating trends cannot be assessed from this filing excerpt. Management implemented control changes during the quarter ended June 30, 2026, but disclosure controls remained ineffective because the previously identified material weakness had not yet operated long enough to be remediated. The most material new risk is Nasdaq's proposed $5 million MVLS requirement, under which the company's MVLS was already less than $5 million as of the filing date.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Control Remediation Implemented
- During the quarter ended June 30, 2026, management implemented multiple compensating controls and completed a redesign of the control environment, including enhanced monitoring, review procedures, and reassignment of responsibilities.
- Additional Hiring No Longer Expected
- Management stated that it does not currently expect to hire additional accounting personnel previously contemplated in the Annual Report, following the control redesign completed during the quarter ended June 30, 2026.
- Nasdaq Requirement Currently Stayed
- The company reported that the SEC stayed approval of Nasdaq's $5 million Market Value of Listed Securities requirement on July 29, 2026, so the requirement was not in effect as of the filing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Weakness Remains
- Disclosure controls and procedures were ineffective as of June 30, 2026 because of a material weakness involving limitations in the accounting software, a limited number of accounting personnel, and insufficient segregation of duties over certain transactions.
- Potential Nasdaq Suspension
- As of the filing date, GRI Bio's Market Value of Listed Securities was less than $5 million. If Nasdaq's requirement becomes effective and MVLS remains below $5 million for 30 consecutive business days, trading could be immediately suspended and delisting proceedings initiated.
- Limited Delisting Cure Protection
- The Nasdaq MVLS requirement provides no cure or compliance period for suspension; although a Hearings Panel may grant an exception of up to 180 days, a hearing request would not automatically stay the suspension.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text. The filing states that cash runway and funding outlook were not discussed quantitatively.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- GRI Bio reported a net loss of $1.998 million for Q1 2026, significantly improved from a loss of $3.046 million in Q1 2025. The company's cash position remains stable at $11 million, while operating cash flow showed a…
- 10-K · January 30, 2026
- GRI Bio is a clinical-stage biopharmaceutical company focused on iNKT/dNKT-targeting oral therapies. Its Phase 2a trial of GRI-0621 in IPF (35 patients enrolled; 19 completed in treatment arm, 9 in placebo) met its…
- 10-Q · November 14, 2025
- GRI Bio reported no revenue and a net loss of $3,359,000 for the quarter ended September 30, 2025 (net loss per share $(1.28)). Operating expenses increased materially year-over-year to $3,365,000 (up $1,235,000 vs.…
- 10-Q · August 14, 2025
- GRI Bio reported a net loss of $(2,892) for Q2 2025 (three months ended June 30, 2025) and loss per share of $(1.31), in line with consensus. Operating expenses increased to $2,897 for the quarter from $2,257 in Q2 2024…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GRI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever